Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M50,078Revenue (TTM) $M19,480Net Margin (%)9.1Altman Z-Score2.2
Enterprise Value $M58,090EPS (TTM) $1.9Operating Margin %12.1Piotroski F-Score6
P/E(ttm)28.4Beneish M-Score-2.4Pre-tax Margin (%)13.7Higher ROA y-yN
Price/Book1.910-y EBITDA Growth Rate %14.6Quick Ratio1.0Cash flow > EarningsY
Price/Sales2.55-y EBITDA Growth Rate %4.7Current Ratio1.3Lower Leverage y-yY
Price/Free Cash Flow41.8y-y EBITDA Growth Rate %-34.5ROA % (ttm)3.5Higher Current Ratio y-yY
Dividend Yield %2.5PEG6.1ROE % (ttm)6.6Less Shares Outstanding y-yN
Payout Ratio %71.0Shares Outstanding M914ROIC % (ttm)3.5Gross Margin Increase y-yY

Gurus Latest Trades with TEVA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
TEVAJulian Robertson 2016-03-31 Reduce-2.02%$53.5 - $65.86
($58.8)
$ 54.79-7%Reduce -40.16%356,200
TEVANWQ Managers 2016-03-31 Add0.49%$53.5 - $65.86
($58.8)
$ 54.79-7%Add 42.10%1,961,208
TEVAFirst Eagle Investment 2016-03-31 Reduce-0.4%$53.5 - $65.86
($58.8)
$ 54.79-7%Reduce -56.18%1,915,660
TEVADavid Dreman 2016-03-31 Buy 0.21%$53.5 - $65.86
($58.8)
$ 54.79-7%New holding33,983
TEVAJohn Paulson 2016-03-31 Add0.08%$53.5 - $65.86
($58.8)
$ 54.79-7%Add 0.95%20,602,200
TEVAVanguard Health Care Fund 2016-03-31 Add0.07%$53.5 - $65.86
($58.8)
$ 54.79-7%Add 9.60%6,356,700
TEVABarrow, Hanley, Mewhinney & Strauss 2016-03-31 Reduce-0.03%$53.5 - $65.86
($58.8)
$ 54.79-7%Reduce -2.99%9,315,460
TEVAJohn Keeley 2016-03-31 Add0.02%$53.5 - $65.86
($58.8)
$ 54.79-7%Add 20.34%43,784
TEVARonald Muhlenkamp 2016-03-31 Add$53.5 - $65.86
($58.8)
$ 54.79-7%Add 0.12%177,160
TEVAJulian Robertson 2015-12-31 Buy 5.04%$55.96 - $66.32
($61.94)
$ 54.79-12%New holding595,300
TEVAJohn Paulson 2015-12-31 Add0.97%$55.96 - $66.32
($61.94)
$ 54.79-12%Add 13.39%20,409,300
TEVANWQ Managers 2015-12-31 Reduce-0.89%$55.96 - $66.32
($61.94)
$ 54.79-12%Reduce -42.70%1,380,143
TEVAVanguard Health Care Fund 2015-12-31 Buy 0.76%$55.96 - $66.32
($61.94)
$ 54.79-12%New holding5,800,000
TEVADavid Dreman 2015-12-31 Sold Out -0.24%$55.96 - $66.32
($61.94)
$ 54.79-12%Sold Out0
TEVAFirst Eagle Investment 2015-12-31 Reduce-0.01%$55.96 - $66.32
($61.94)
$ 54.79-12%Reduce -2.14%4,371,619
TEVABarrow, Hanley, Mewhinney & Strauss 2015-12-31 Add0.01%$55.96 - $66.32
($61.94)
$ 54.79-12%Add 0.84%9,602,463
TEVAJohn Keeley 2015-12-31 Add$55.96 - $66.32
($61.94)
$ 54.79-12%Add 1.10%36,385
TEVAJohn Paulson 2015-09-30 Add4.82%$55.08 - $72
($64.84)
$ 54.79-15%Add 786.48%18,000,000
TEVANWQ Managers 2015-09-30 Reduce-0.46%$55.08 - $72
($64.84)
$ 54.79-15%Reduce -19.29%2,408,826
TEVAGeorge Soros 2015-09-30 Sold Out -0.26%$55.08 - $72
($64.84)
$ 54.79-15%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

TEVA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


TEVA: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about TEVA:

    News about TEVA:

    Articles On GuruFocus.com
    Siegfried Holdings, Held by Tweedy Browne, Way Undervalued Jul 22 2016 
    Andreas Halvorsen Buys Facebook, Amazon, MasterCard Jun 14 2016 
    Growing Generic Drug Market a Good Opportuity for 2 India Firms May 30 2016 
    Stocks Near 52-Week Lows May 26 2016 
    John Keeley Comments on Teva Pharmaceuticals Apr 26 2016 
    Pfizer-Allergen Merger Deal End Hurts Some Funds But Helps Many Apr 08 2016 
    Time To Buy Allergan Apr 06 2016 
    Health Care Investor Larry Robbins Buys HCA Holdings, Cigna Mar 31 2016 
    Fight Market Malaise with These Four Sector Strategies Mar 30 2016 
    Bernard Horn Comments on Teva Pharmaceutical Mar 21 2016 

    More From Other Websites
    Teva, Allergan win U.S. antitrust approval for generics deal Jul 27 2016
    Teva, Allergan win U.S. antitrust approval for generics deal Jul 27 2016
    Teva, Allergan win U.S. antitrust approval for generics deal Jul 27 2016
    Teva, Allergan win U.S. antitrust approval for generics deal Jul 27 2016
    Teva expect to close $40.5B Allergan generic deal next week Jul 27 2016
    Teva expect to close $40.5B Allergan generic deal next week Jul 27 2016
    Teva to Report Second Quarter 2016 Financial Results on August 4, 2016 Jul 27 2016
    [$$] Teva, Allergan Get FTC Approval for Generics Purchase Jul 27 2016
    FTC approves Teva's $40.5B deal for Allergan's generics business Jul 27 2016
    Teva Wins U.S. Nod for Actavis After Divestiture of 79 Drugs Jul 27 2016
    Teva purchase of Allergan generics business approved with conditions Jul 27 2016
    2:37 pm Teva Pharma confirms FTC clearance for Actavis (AGN unit) generics acquisition; transaction... Jul 27 2016
    Teva Receives Clearance from the U.S. Federal Trade Commission for Actavis Generics Acquisition Jul 27 2016
    Teva Wins U.S. Approval to Buy Actavis After Selling Generics Jul 27 2016
    Short Sellers Get Selective on Major Pharma Jul 27 2016
    Alder Biopharma Migraine Drug Holds Up After 6 Months Jul 25 2016
    Investor Demand for U.S. Corporate Bond Remains Insatiable Jul 25 2016
    Specialty Pharma: Earnings Better Be Good…or Else Jul 25 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)